DrugDashboards

Liraglutide

Liraglutide · LIRAGLUTIDE 6 mg/mL · Injection, Solution · Subcutaneous · Teva Pharmaceuticals, Inc.

NDC 00480-7250-46 · 5 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The brand (Saxenda) runs $87.14 per mL — 1.8× more. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.3% of the time — roughly 2× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$47.69per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$75.15per dosage unitgross, before rebates — matched by drug name · 2024
  • Medicaid generic ceiling (FUL)$64.20per MLweighted avg manufacturer price $36.6853 · Jul 1, 2026135% of what pharmacies pay — higher than 76% of drugs with this benchmark

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$25.00$50.00$75.00Dec 2025Sep 2026$47.69
9 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$1,165.54
Reported to Texas DSHS · 2026 annual filing · Teva Pharmaceuticals, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$1.6M
1,691 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20● Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10
  • manufacturer plans to discontinue+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.3%chance of a new FDA shortage posting for liraglutide (injectable) in the next 90 days

sterile injectable · sole-source market · 1 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is 2× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $772.57 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA214568
TE code
AP2
Approval date
Aug 27, 2025
Patents / exclusivity
0 patents, 1 exclusivities
TypeNumber / codeExpires
exclusivityPCFeb 24, 2026

Shortage history

  • Planned discontinuation — Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)May 14, 2026
  • Planned discontinuation — Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)Jul 18, 2023

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Liraglutide (Injection, Solution)

LabelerStrengthFirst seenLast seen
Cipla USA Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 3, 2026
Orbicular Pharmaceutical Technologies Private LimitedLIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 3, 2026
A-S Medication SolutionsLIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Biocon Pharma Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPLIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Teva Pharmaceuticals, Inc.LIRAGLUTIDE 6 mg/mLJul 15, 2026Sep 2, 2026
Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)LIRAGLUTIDE 18 mg/3mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Liraglutide — NDC 00480-7250-46," retrieved September 3, 2026, https://drugdashboards.com/drug/00480725046.

Free to cite with attribution — see how the data is put together.